First Ovarian Cancer Patient Dosed in Phase 1 Trial of Solid-Tumor Therapy Celyad

First Ovarian Cancer Patient Dosed in Phase 1 Trial of Solid-Tumor Therapy Celyad
The U.S. arm of a Phase 1 clinical trial of Celyad as a solid-tumor treatment has kicked off with the dosing of the first ovarian cancer patient at the Roswell Park Cancer Institute in Buffalo, New York. The THINK trial (NCT03018405) is in the midst of testing the second of three doses to determine an optimum level of Celyad.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *